B. Weigel

E. Rudzinski, C. Lockwood, B. Weigel, 2022, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)

Rachel A. Kudgus, S. Goldstein, J. Reid, 2018, Cancer.

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra‐cranial solid tumors: A Children's Oncology Group Phase I Consortium report

C. Ahern, T. Cripe, B. Weigel, 2015, Pediatric blood & cancer.

Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

Rachel A. Kudgus, K. Cole, J. Maris, 2019, Clinical Cancer Research.

PDCT-04. PHASE 1 TRIAL OF WEE1 KINASE INHIBITOR AZD1775 COMBINED WITH RADIATION THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP PHASE 1 PILOT CONSORTIUM (ADVL1217)

D. Haas-Kogan, S. Mueller, J. Reid, 2018, Neuro-Oncology.

Identification of aggressive Gardner syndrome phenotype associated with a de novo APC variant, c.4666dup

Z. Niu, Mai‐Lan Ho, L. Schimmenti, 2019, Cold Spring Harbor molecular case studies.

Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

J. Reid, C. Minard, M. Nelson, 2019, Pediatric blood & cancer.

Racial and Ethnic Differences in Sarcoma Incidence Are Independent of Census-Tract Socioeconomic Status

J. Poynter, L. Spector, B. Weigel, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

K. Wilner, P. Adamson, F. Balis, 2021, Clinical Cancer Research.

Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors

K. Dusenbery, J. Perentesis, M. Verneris, 2006, Bone Marrow Transplantation.

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.

D. Munn, V. Kuchroo, M. Hirashima, 2011, Blood.

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

Helen X. Chen, L. Doyle, L. Wagner, 2015, Pediatric blood & cancer.

Phenotype in Mice with Disseminated Acute Myelogenous Leukemia Running title: PD-1+Tim-3+ CD8+T-cells induced by AML are dysfunctional

D. Munn, V. Kuchroo, W. Murphy, 2011 .

A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112)

C. Ahern, J. Reid, M. Fouladi, 2013, Clinical Cancer Research.

Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

P. Meltzer, J. Trent, E. Kleinerman, 2014, Clinical Cancer Research.

A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase‐Clinical Trial Network (PEP‐CTN)

J. Trepel, B. Chang, J. Reid, 2021, Pediatric blood & cancer.

Strategies for New Agent Development in Pediatric Sarcomas

B. Weigel, Emily G Greengard, 2020 .

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

S. Baruchel, P. Adamson, F. Balis, 2012, Clinical Cancer Research.

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

D. Munn, J. Tolar, B. Levine, 2010, Blood.

ACCELERATE - Five years accelerating cancer drug development for children and adolescents.

P. Kearns, G. Vassal, P. Adamson, 2022, European journal of cancer.

A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)

C. Wetmore, J. Reid, A. Scheck, 2021, Pediatric blood & cancer.

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors

T. Laetsch, S. Borinstein, L. Mascarenhas, 2021, Cancer medicine.

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study

Rachel A. Kudgus, Steve Y. Cho, Malcolm A. Smith, 2020, Cancer.

Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.

R. Randall, J. Reid, A. Buxton, 2019, European journal of cancer.

Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse

M. Verneris, M. Burke, B. Weigel, 2011, Bone Marrow Transplantation.

Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report

B. Weigel, B. Bidadi, Justin Kirkham, 2020, Pediatric blood & cancer.

Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses.

Narender Nath, B. Blazar, P. Taylor, 2002, Blood.

Associations of Socioeconomic Status, Public vs Private Insurance, and Race/Ethnicity With Metastatic Sarcoma at Diagnosis

J. Poynter, L. Spector, B. Weigel, 2020, JAMA network open.

Prognostic Factors for Development of Subsequent Metastases in Localized Osteosarcoma: A Systematic Review and Identification of Literature Gaps

L. Spector, B. Weigel, Emily G Greengard, 2020, Sarcoma.

Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.

S. Baruchel, C. Ahern, J. Reid, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma.

D. Largaespada, Subbaya Subramanian, A. Rizzardi, 2013, Human pathology.

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma

James R. Anderson, D. Rodeberg, S. Spunt, 2018, Cancer.

First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium

F. Balis, Y. Mossé, C. Minard, 2016, Cancer Chemotherapy and Pharmacology.

Patterns of chemotherapy‐induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

James R. Anderson, D. Hawkins, A. Rosenberg, 2017, Pediatric blood & cancer.

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)

C. Ahern, J. Reid, M. Ames, 2013, Pediatric blood & cancer.

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

M. Loh, C. Ahern, J. Reid, 2015, Pediatric blood & cancer.

A phase 1 trial of temsirolimus and intensive re‐induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)

D. Teachey, M. Borowitz, C. Minard, 2017, British journal of haematology.

Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

Helen X. Chen, C. Ahern, P. Adamson, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of Seneca Valley Virus (NTX‐010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group

C. Rudin, C. Ahern, T. Cripe, 2015, Pediatric blood & cancer.

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, D. Rodeberg, D. Hawkins, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early results from Children's Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).

James R. Anderson, D. Rodeberg, D. Hawkins, 2015 .

Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial

C. Minard, Erin H. Breese, S. Tasian, 2022, Blood.

Osteosarcoma in the first decade of life.

J. Perentesis, R. Nagarajan, B. Weigel, 2003, Medical and pediatric oncology.

Prolonged subcutaneous administration of 852A, a novel systemic toll‐like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies

Jeffrey S. Miller, D. Weisdorf, B. Blazar, 2012, American journal of hematology.

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.

D. Hawkins, B. Widemann, T. Zwerdling, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

S. Baruchel, A. Chen, C. Ahern, 2012, Clinical Cancer Research.

A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia

Jeffrey S. Miller, S. Pounds, M. Verneris, 2014, American journal of hematology.

Retinoblastoma and Hirschsprung disease in a patient with interstitial deletion of chromosome 13.

J. Neglia, T. Young, M. Pierpont, 1998, American journal of medical genetics.

Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials

A. Naranjo, W. London, R. Bagatell, 2017, Cancer.

A Phase II Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

Jeffrey S. Miller, M. Verneris, V. Bachanova, 2012 .

Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Juan C. Vasquez, C. Arndt, W. Xue, 2023, Pediatric blood & cancer.

Metabolic response as assessed by 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

D. Rodeberg, S. Spunt, D. Hawkins, 2020, Cancer medicine.

Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

David C. Jones, P. Kearns, X. Paoletti, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of the c‐Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

Rachel A. Kudgus, J. Perentesis, J. Reid, 2017, Pediatric blood & cancer.

Killing the Killer: Natural Killer Cells to Treat Ewing's Sarcoma

Y. Ahn, B. Weigel, M. Verneris, 2010, Clinical Cancer Research.

A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study

R. Gilbertson, J. Neglia, P. Adamson, 2007, Clinical Cancer Research.

Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).

B. Widemann, J. Reid, D. Barkauskas, 2021 .

Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS).

James R. Anderson, J. Michalski, D. Hawkins, 2010 .

Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma

K. Cole, J. Maris, J. Reid, 2023, Cancer.

A phase II study of pazopanib in children, adolescents, and young adults with refractory solid tumors.

H. Tada, P. Langmuir, B. Weigel, 2015 .

Phase 1 trial of ontuxizumab (MORAb‐004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)

R. Norris, J. Reid, C. Minard, 2018, Pediatric blood & cancer.

A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)

J. Reid, C. Minard, G. Martinez, 2018, Pediatric blood & cancer.

A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).

J. Reid, C. Minard, S. Voss, 2019, Journal of Clinical Oncology.

Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning

G. Cutter, Subbaya Subramanian, J. Modiano, 2021, bioRxiv.

Study of 17-Allylaminogeldanamycin in Relapsed / Refractory Pediatric Patients with SolidTumors : AChildren ’ s Oncology Group Study

R. Gilbertson, J. Neglia, P. Adamson, 2007 .

A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study.

C. Ahern, C. Roberts, P. Adamson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study.

R. Norris, C. Ahern, R. Bagatell, 2012 .

Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium Trial.

S. Baruchel, C. Ahern, P. Adamson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Sara M. Federico, M. Kool, G. Vassal, 2023, European journal of cancer.

ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?

G. Vassal, A. Pappo, G. Reaman, 2022, The Lancet. Oncology.

A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.

K. Davis, C. Mackall, J. Reid, 2022, Clinical Cancer Research.

Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study

M. Loh, D. Teachey, R. Norris, 2020 .

Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics

B. Weigel, E. Fox, D. W. Parsons, 2023, Pediatric blood & cancer.

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.

B. Crompton, J. Reid, E. Rudzinski, 2023, Journal of Clinical Oncology.

Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1)

M. Loh, D. Teachey, R. Norris, 2023, Pediatric blood & cancer.

Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent

J. Reid, A. Buxton, K. Janeway, 2020 .

Outcome of recurrent osteosarcoma patients enrolled in seven phase II trials through CCG, POG, and COG: Learning from the past to move forward.

D. Hawkins, B. Widemann, T. Zwerdling, 2015 .

D. Hawkins, B. Widemann, T. Zwerdling, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group

Helen X. Chen, P. Adamson, J. Reid, 2014, Pediatric blood & cancer.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

D. Munn, J. Tolar, B. Levine, 2009, Blood.

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712

J. Reid, T. Horton, C. Minard, 2023, Pediatric blood & cancer.

Sara M. Federico, M. Kool, G. Vassal, 2023, European journal of cancer.

A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study (ADVL1011).

C. Ahern, P. Brown, K. Rabin, 2014 .

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

S. Roy-Chowdhuri, K. Janeway, A. Jaju, 2024, The Oncologist.

A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614)

B. Moriarity, J. Reid, C. Minard, 2024, Pediatric blood & cancer.